Pre IPO Neusoft Xikang Healthcare Technology - Some Points Worth the Attention
414 Views04 May 2023 08:55
Xikang’s business model has its logic.But due to the restrictions imposed by cities, the scalability is uncertain.Without strong 2B business as “entry point” , Xikang's 2C business lacks pricing power
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (May.26)- 9th National VBP, China's Strength in ADC Field, Ovctek, Eyebright28 May 2023
- Pre-IPO Cutia Therapeutics (CUT HK) - Outlook Is Uncertain Due to Unique Pipeline Characteristics25 May 2023
- Shanghai Tofflon Science (300171.CH) 2022/23Q1 - It's Better Not to Go Against the Trend08 May 2023
- Pre IPO Neusoft Xikang Healthcare Technology - Some Points Worth the Attention04 May 2023
- JD Health (6618.HK) - Business Transformation Is Still Difficult06 Apr 2023
- ClouDr Group (9955.HK) - “A Dark Horse” to Beat JD Health05 Apr 2023
- Pre-IPO Neusoft Xikang Holdings - The Business Model and the Concerns08 Jul 2021
x